Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Surg Oncol Clin N Am. 2010 Jan;19(1):101–113. doi: 10.1016/j.soc.2009.09.004
# Patients
Randomized		 Study
Groups		 Stratification Significance
Demonstrated		 % Change
Identified in Trial
312 Sunitinib n = 207

Placebo n = 105		 Based on prior outcome on imatinib treatment: progression within 6 months vs progression beyond 6 months or intolerance to imatinib Improvement in progression-free survival Hazard ratio 0.33 (95% CI 0.23–0.47, p < 0.0001)